Table 2 Association of STK3 rs7827435 with BCR in localized prostate cancer patients treated with RP

From: Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer

 

Univariate analysis

Multivariate analysisa

Gene SNP

Discovery

Replication

Combined

 

Discovery

Replication

Combined

Genotype

No BCR

BCR

HR (95% CI)

P

No BCR

BCR

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

STK3 rs7827435

                

AA

40

23

1.00

 

25

29

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

AT

87

38

0.80 (0.47–1.34)

0.387

53

59

1.10 (0.70–1.72)

0.690

0.96 (0.68–1.36)

0.83

0.93 (0.54–1.59)

0.785

0.90 (0.57–1.41)

0.635

0.91 (0.64–1.29)

0.61

TT

40

12

0.49 (0.25–0.99)

0.048

24

16

0.60 (0.32–1.10)

0.097

0.55 (0.34–0.86)

0.01

0.43 (0.20–0.89)

0.024

0.49 (0.26–0.93)

0.028

0.46 (0.29–0.76)

0.002

AT/TT vs AA

  

0.69 (0.42–1.14)

0.147

  

0.93 (0.60–1.42)

0.725

0.82 (0.59–1.13)

0.23

0.73 (0.44–1.21)

0.220

0.76 (0.49–1.18)

0.220

0.75 (0.54–1.04)

0.08

TT vs AA/AT

  

0.57 (0.31–1.07)

0.079

  

0.56 (0.33–0.96)

0.034

0.56 (0.38–0.84)

0.005

0.45 (0.23–0.87)

0.018

0.53 (0.30–0.93)

0.026

0.49 (0.32–0.76)

0.001

Trend

  

0.72 (0.52–1.00)

0.048

  

0.81 (0.62–1.07)

0.133

0.77 (0.63–0.95)

0.01

0.70 (0.50–0.97)

0.030

0.73 (0.55–0.98)

0.033

0.72 (0.58–0.89)

0.003

  1. Abbreviations: BCR, biochemical recurrence; RP, radical prostatectomy; SNP, single nucleotide polymorphism; HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen.
  2. aAdjusted by age, PSA at diagnosis, pathologic Gleason score and pathologic stage.
  3. P < 0.05 are in boldface.